A population-based study of chronic neutrophilic leukemia in the United States: 2004 to 2015 von Ruan, Gordon, Smith, Caleb, Day, Courtney N., Harmsen, William S., Zblewski, Darci, Alkhateeb, Hassan, Al-Kali, Aref, Litzow, Mark Robert, Hogan, William J., Szuber, Natasha, Gangat, Naseema, Patnaik, Mrinal, Pardanani, Animesh Dev, Elliott, Michelle A., Tefferi, Ayalew, Go, Ronald S., Shah, Mithun Vinod

Volltext

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with relapsed/refractory chronic myelomonocytic leukemia (CMML) von Patnaik, Mrinal Mahesh, Ali, Haris, Gupta, Vikas, Schiller, Gary J., Lee, Sangmin, Yacoub, Abdulraheem, Talpaz, Moshe, Wysowskyj, Halyna, Shemesh, Shay, Chen, Janice, Brooks, Christopher, Poradosu, Enrique, Rupprecht, Nicole, Pardanani, Animesh Dev, Tefferi, Ayalew, Wang, Eunice S., Taparia, Minakshi, Verstovsek, Srdan, Khoury, Joseph, Pemmaraju, Naveen

Volltext

Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis von Pemmaraju, Naveen, Ali, Haris, Gupta, Vikas, Schiller, Gary J., Lee, Sangmin, Yacoub, Abdulraheem, Talpaz, Moshe, Wysowskyj, Halyna, Shemesh, Shay, Chen, Janice, Brooks, Christopher, Poradosu, Enrique, Rupprecht, Nicole, Pardanani, Animesh Dev, Tefferi, Ayalew, Wang, Eunice S., Taparia, Minakshi, Verstovsek, Srdan, Khoury, Joseph, Patnaik, Mrinal Mahesh

Volltext

Absolute neutrophil count (ANC) cutoff in cancer clinical trials: Implications for minority accrual in the United States (US) von Gunaratne, Madugodaralalage, Abeykoon, Jithma P., Wolanskyj-Spinner, Alexandra P., Sridharan, Meera, Hook, Carl C., Rouse, Rachelle, Elliott, Michelle A., Ashrani, Aneel A., Pardanani, Animesh Dev, Pruthi, Rajiv, Go, Ronald S.

Volltext

Effect of echocardiogram prior to induction therapy for acute myeloid leukemia on detection of cardiac dysfunction and treatment modifications von Yui, Jennifer C., Mudireddy, Mythri, Patnaik, Mrinal, Gangat, Naseema, Al-Kali, Aref, Elliott, Michelle A., Hogan, William J., Hook, Carl C., Wolanskyj, Alexandra P., Pardanani, Animesh Dev, Villarraga, Hector R., Litzow, Mark Robert, Tefferi, Ayalew, Begna, Kebede

Volltext

Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) von Cortes, Jorge E., Faderl, Stefan, Pagel, John, Jung, Chul Won, Yoon, Sung-Soo, Koh, Youngil, Pardanani, Animesh Dev, Hauptschein, Robert S, Lee, Kyoung-June, Lee, Je-Hwan

Volltext

Phase I study of lurbinectedin (PM11083) in patients with advanced AML and MDS von Benton, Christopher Brent, Rodriguez Diaz -Pavon, Jose, Maiti, Abhishek, Daver, Naval Guastad, Ravandi, Farhad, Jain, Nitin, Alvarado, Yesid, Jabbour, Elias, Pierce, Sherry, Kwari, Monica, Santos, Margarida A, Martinez, Sara, Siguero, Mariano, Tefferi, Ayalew, Cortes, Jorge E., Kantarjian, Hagop M., Pardanani, Animesh Dev, Garcia-Manero, Guillermo

Volltext

Modulation of plasma cytokines and its association with clinical response to treatment with the JAK2-selective inhibitor SAR302503 in myelofibrosis (MF) von Talpaz, Moshe, Jamieson, Catriona H. M., Gabrail, Nashat Y., Lebedinsky, Claudia, Liu, Feng, Cao, Hui, Tefferi, Ayalew, Pardanani, Animesh Dev

Volltext

Updated results from a randomized phase II dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with myelofibrosis (MF) von Pardanani, Animesh Dev, Jamieson, Catriona H. M., Gabrail, Nashat Y., Lebedinsky, Claudia, Gao, Guozhi, Patki, Abhay, Liu, Feng, Tefferi, Ayalew, Talpaz, Moshe

Volltext

A randomized phase II, open-label trial of orally administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant t... von Tefferi, Ayalew, Cortes, Jorge E., Hochhaus, Andreas, Kiladjian, Jean-Jacques, Mesa, Ruben A., Pardanani, Animesh Dev, Lebedinsky, Claudia, Neumann, Frank, Hsu, Karl, Vannucchi, Alessandro M.

Volltext

JAKARTA: A phase III, multicenter, randomized, double-blind, placebo-controlled, three-arm study of SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF... von Pardanani, Animesh Dev, Cortes, Jorge E., Cervantes, Francisco, Harrison, Claire N, Passamonti, Francesco, Lebedinsky, Claudia, Neumann, Frank, Cohen, Pamela, Tefferi, Ayalew

Volltext

CDKN2A-deletion to predict relapse in adult B-cell acute lymphoblastic leukemia (B-ALL) von Singh, Preet Paul, Ketterling, Rhett, Litzow, Mark Robert, Tefferi, Ayalew, Patnaik, Mrinal M., Pardanani, Animesh Dev, Hogan, William J., Letendre, Louis, Elliott, Michelle A., Begna, Kebede, Wolanskyj, Alexandra P., Al-Kali, Aref

Volltext